All articles tagged with #preclinical
Researchers report FLAV-27, a G9a/EHMT2 inhibitor, epigenetically reprograms neuronal gene expression to combat Alzheimer's pathology; in cell cultures, nematodes, and mice it reduced disease features and restored memory and synaptic function, suggesting a broader upstream approach beyond amyloid and tau. The compound has not yet been tested in humans and would require extensive safety and regulatory steps before trials.
University of Barcelona researchers report that FLAV-27, a first-in-class SAM-competitive G9a inhibitor, reverses cognitive deficits in multiple Alzheimer’s disease mouse models by reprogramming neuronal gene activity, a mechanism distinct from beta-amyloid–targeting drugs; the compound is currently in preclinical stages and could represent a disease-modifying approach pending human safety data.
The National Cancer Institute is conducting a preclinical study of ivermectin as a potential cancer therapy, with results expected in months, a move that has drawn opposition from some scientists who say there is no solid evidence and warn about misinforming patients, even as officials and influencers promote the idea.
Metagenomi, a gene editing company, has set a price range for its proposed initial public offering, expecting to raise about $87 million if it prices at $16 per share. The California startup plans to go public later this week by selling 6.25 million shares, with the potential for increased proceeds if the company upsizes before landing on Nasdaq.